Skip to Content

Isavuconazonium Disease Interactions

There are 2 disease interactions with isavuconazonium:

Major

Isavuconazonium (Includes isavuconazonium) ↔ short QT

Severe Potential Hazard, Moderate plausibility. Applies to: Short QT Syndrome

Isavuconazonium has shown to shorten the QTc interval in a concentration- related manner. The use of this drug is contraindicated in patients with familial short QT syndrome.

Moderate

Isavuconazonium (Includes isavuconazonium) ↔ liver disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The use of isavuconazonium has been associated with hepatic adverse reactions. Liver function tests should be performed at the start of therapy and periodically in patients with preexisting hepatic abnormalities. Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur. Isavuconazonium has not been studies in patients with severe hepatic impairment (Child-Pugh Class C) and should be used in these patients only when the benefits outweigh the risk.

Isavuconazonium drug interactions

There are 543 drug interactions with isavuconazonium

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide